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Abstract
In June 2012, Israeli guidelines for laboratories were published deﬁning the recommended methods for diagnosis of Clostridium difﬁcile
infection (CDI). We conducted this survey to examine the effects of the new recommendations on the proportions of rejected and positive
samples by the different methods. A survey was mailed to the directors of all general hospital (GH) and health maintenance organization
(HMO) clinical microbiology laboratories. The report was divided into two periods, before and after implementation of the guidelines.
Surveys were completed by 13/28 GH laboratories and 5/6 HMO laboratories. All 18 of these laboratories used C. difﬁcile toxin (CDT)
enzyme immunoassay alone during the ﬁrst period of the survey. In the second period, nine laboratories (Group A) used CDT-PCR: two of
them used this method exclusively while the other seven used it to resolve most (>90%) of the discrepant results (glutamate dehydrogenase
antigen (GDH) +/CDT]. The other nine laboratories (Group B) used combined GDH/CDT assay, using CDT PCR in only a minority
(< 20%) of GDH+/CDT cases. The overall proportion of rejected samples increased from 9.5% in the ﬁrst period to 13.9% in the second
(p <0.001). Between the ﬁrst and second periods the proportion of positive samples increased from 9.0% to 11.6% in group A laboratories
(p <0.001), but decreased from 12.9% to 9.7% in group B laboratories (p <0.001). Implementation of the guidelines has resulted in a
signiﬁcant increase in the proportion of rejected samples and in the proportion testing positive, suggesting more appropriate test utilization
and improved sensitivity in the laboratory diagnosis of CDI.
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Introduction
Clostridium difﬁcile is one of the leading causes of health-
care-associated infection [1] and may be the most common
cause of bacterial gastroenteritis in developed countries [2].
Since the beginning of the millennium, there has been an
increase in the incidence of Clostridium difﬁcile infection (CDI)
and possibly also in the severity of illness caused by it in certain
parts of the USA and Canada [1,3]. These changes are
attributed in part to the spread of an epidemic clone, BI/NAP1/
027, that has since been identiﬁed also in Europe, East Asia and
Australia [1].
Concomitant with these epidemiological changes, there have
been dramatic changes in the methodology available for the
laboratory diagnosis of CDI. Methods such as toxigenic culture
or cell culture cytotoxicity neutralization assay that have
traditionally been used by reference laboratories are still
considered the gold standard [4]. However, most clinical
laboratories have been using enzyme immunoassay (EIA) for
the C. difﬁcile toxins A and B (CDT EIA) as their routine
diagnostic method [2]. The accumulation of data from numer-
ous studies has shown variable and frequently low sensitivity
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values ranging from 43% to 98% [4]. The speciﬁcity of these
tests appears to be higher. However, the positive predictive
values are as low as 50% in some studies [4]. Therefore, several
recent guidelines [5,6], although not all [7], have stipulated that
CDT EIA cannot be used as a sole method for diagnosis of CDI.
Instead, other methods, including CDT PCR and glutamate
dehydrogenase (GDH) are recommended, the latter requiring
conﬁrmation of toxin production by an additional method.
Despite these updates in the guidelines, several national [8–10]
and international [11] surveys have found that these newer
methods are used by only a minority of laboratories, highlight-
ing the potential for under-diagnosis of CDI.
The diagnosis of CDI requires the presence of both
relevant clinical symptoms as well as laboratory conﬁrmation,
because toxigenic C. difﬁcile can be detected in asymptomatic
individuals [5]. Therefore, professional guidelines [5–7] have
recommended the application of sample selection criteria,
such as the avoidance of testing repeat samples or samples
taken from young infants. The extent to which such criteria
are applied can have a signiﬁcant inﬂuence on the proportion
of samples testing positive. This effect can be even more
pronounced with the application of the newer, more sensitive
diagnostic methods. However, the use of rejection criteria
has been addressed by only one [8] of the national [9,10] and
international [8,11] surveys conducted, and none of these
evaluated the effect of the changing diagnostic methodology
on the proportion testing positive.
In Israel, ofﬁcial guidelines were issued by the Ministry of
Health in June 2012 [12]. Following the publication of these
guidelines, we conducted a national survey that aimed to (i)
examine the methods and policies regarding CDI diagnosis in
Israel, (ii) study the policies regarding sample selection and the
proportions of rejected samples, and (iii) assess the propor-
tion of positive samples by the different methods, before and
after implementation of the newer diagnostic methods.
Methods
Study design and questionnaire
This was a nationwide survey of clinical microbiology laborato-
ries, regarding the practices of CDI microbiological diagnosis.
The survey includedawrittenquestionnaire sent to thedirectors
of participating laboratories in August 2012. Participating
laboratories included those of all general hospitals (GH) as well
as those of the Health Maintenance Organizations (HMO). The
latter serve both community patients and afﬁliated long-term
care facilities (LTCF). Three laboratories located in LTCF and
one located in a private hospital (<200 beds) were not
approached. In the survey the directors were asked to provide
data regarding the current method of CDI diagnosis (type of test
and manufacturer), the duration of its use in the facility, and
information regarding the previously used method. They were
also asked to indicate whether they apply criteria for sample
acceptance and if so, since when. All participating laboratories
provided monthly data regarding the total number of CDI tests,
the numberof rejected samples, the numberof negative tests and
the number of positive tests. They were asked to provide data
regarding the methodology currently in use as well as that used
previously. Data were collected mainly retrospectively: labora-
torieswere asked to submit data for up to12 months previously,
but were also allowed to collect and submit data prospectively
from survey initiation (August 2012) until December 2012.
Ofﬁcial guidelines for the diagnosis of CDI in Israel
The ﬁrst ofﬁcial guidelines regarding the diagnosis of CDI in
Israel were issued by the Ministry of Health in 2000. Clinical
laboratories were instructed to use EIA that test for both toxins
A and B [13]. In June 2012, a new guidelines documentwas issued
[12]. In these guidelines, instructions regarding both sample
acceptance criteria and analytical procedures were given.
Criteria for sample rejection were given in accordance with
the Infectious Diseases Society of America guidelines [5],
including: (i) rejection of solid stool samples (with the exception
of cases in which ileus is the presenting symptom), (ii)
non-repetition of testing within 2 weeks of a positive test or
1 week of a negative test, and (iii) rejection of samples from
neonates. The analytical procedures recommended offered two
options: (i) screening using GDH antigen testing, with conﬁr-
mation of the presence of CDT in positive samples by CDT EIA
orCDTPCR,with PCR recommended in the event of discrepant
results by GDH and EIA testing; (ii) CDT PCR as a single test.
The guidelines did not include speciﬁc recommendations for the
indications for CDI testing, which was done per request only.
Deﬁnitions
Participating laboratories were classiﬁed according to institu-
tion type and the diagnostic method in use at the time of the
survey (second period).
Institutions. Laboratory classiﬁcation according to institution
type was as follows: group 1, tertiary-care hospital; group 2,
non-tertiary-care GH, >400 beds; group 3, GH, <400 beds;
group 4, HMO laboratories. The HMO laboratories varied
widely in the volume of samples handled; all serve outpatient
clinics as well as LTCFs.
Diagnostic methods. Laboratory classiﬁcation according to
diagnostic method was as follows: group A, use of CDT PCR
exclusively or in most cases (>90%) of GDH+/CDT samples;
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group B, no use of CDT PCR or use in only a minority (<20%)
of GDH+/CDT samples. Both groups were using CDT EIA
during the ﬁrst period. Hence, the time periods were deﬁned
individually for each laboratory, according to the time of
transition between the methods. We included only laborato-
ries already using GDH/CDT and/or CDT PCR and able to
provide results for a span of between 6 and 12 months for
each period. Although it provided data for only 3 months of
the second period, we included laboratory no. 4 so as to
include data also from the only laboratory that was using an
in-house CDT PCR assay.
Data analysis
The total number of patients with CDI was deﬁned as the total
number of CDT EIA-positive samples plus the number of CDT
PCR-positive/CDT EIA-negative samples. Sensitivity of CDT
EIA was calculated as the number of CDT EIA-positive samples
(true positives) divided by the total number of patients with
CDI.
Categorical parameters were compared using the Pearson
v2 test. Values of p ≤0.05 were considered as representing a
signiﬁcant difference between the groups. Multivariable analysis
was performed using binary logistic regression prediction
models constructed via forward stepwise progression. Data
were analysed using the SPSS software package version 15.0
(SPSS, Chicago, IL, USA).
Results
General characteristics and sample rejection policies of
participating laboratories
Overall, 18 laboratories completed the survey. The selection
process is presented in Fig. 1. Participating laboratories
included those from four group one hospitals, seven group
two hospitals and two group three hospitals, as well as ten
HMO-based laboratories (Fig. 1, Table 1)—ﬁve covering 8286
(52%) of Israel’s 15 937 acute-care hospital beds and ﬁve
covering 91% of HMO-insured patients.
The transition between the two periods occurred in 2010
in three laboratories, 2011 in eight laboratories and 2012 in
seven laboratories (Table 1). During the second period, two
laboratories were using CDT PCR as their only method
(Table 1) and the rest of the laboratories were using a
combined GDH and CDT EIA test (GDH/CDT) as their
primary method, almost all from a single manufacturer (C.
DIFF QUIK CHEK COMPLETE, TECHLAB, Blacksburg,
VA, USA). The Xpert C. difﬁcile test (Cepheid, Sunnyvale,
CA, USA) was used by the majority of the laboratories;
exceptions were laboratory no. 4, which used an in-house
assay, and labs no. 6, 12 and 18, which used the Illumigene
C. difﬁcile (Meridian Bioscience, Inc., Cincinnati, OH, USA)
assay.
Sample rejection/acceptance criteria were applied system-
atically by all except for two HMO-based laboratories
(Table 1). The rejection criteria most commonly applied were
recently diagnosed CDI (15/18 patient samples) and formed
stool (14/18 patient samples). Overall, the proportion of
patient samples rejected increased signiﬁcantly from 9.5% in
the ﬁrst to 13.9% in the second period (p <0.001, Table 2).
The extent of this change was related to the application of
rejection criteria (Table 1). In laboratories in which rejection
criteria were used in both periods (laboratories nos. 2–4, 9,
12, 17, 18), the proportion of rejected samples increased from
9.9% to 11.9%, (p <0.001) whereas in laboratories that applied
them only in the second period (laboratories nos. 1, 5–8, 10,
11, 13, 16) this proportion increased from 9.5% to 19%
(p <0.001). Moreover, in the two laboratories that did not
FIG. 1. Recruitment and classiﬁcation of participating laboratories.
GH, general hospital; HMO, health maintenance organization; CDT,
Clostridium difﬁcile toxin; GDH, glutamate dehydrogenase antigen.
Laboratories were classiﬁed according to their use of CDT PCR in the
second period as follows: group A, if they were using CDT PCR
exclusively or in most cases (>90%) of GDH+/CDT samples; group
B, if they did not perform CDT PCR at all or in only a minority (<20%)
of GDH+/CDT samples.
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apply any criteria (nos. 14, 15), the proportion decreased from
3.5% to 1% (p <0.001). The proportion did not change
signiﬁcantly in the HMO laboratories (nos. 14–18, p 0.199,
Table 2). The proportion rejected was signiﬁcantly higher
(p <0.001) in group A compared with group B laboratories in
both periods. However, the inter-period proportion rejected
increased in both groups, by 5.5% and 3.5%, in groups A and B,
respectively.
Proportion positive among laboratories and periods
The proportions of positive samples were calculated based on
reports of a positive CDT EIA in the two periods or positive
CDT PCR in the second period (Table 2). The total propor-
tion positive was 12.1% in the ﬁrst period and did not change
signiﬁcantly in the second period. However, this proportion
increased in group A from 8.7% to 12% (p <0.001) but
decreased in group B from 15.2% to 11.9% (p <0.001).
Accordingly, it was higher in group B than in group A in the
ﬁrst period (15.2% vs. 8.7%, respectively, p <0.001) but was
almost identical in both groups in the second period (p 0.87).
The proportion positive increased signiﬁcantly in ﬁve of nine
group A laboratories and decreased signiﬁcantly in four of
nine group B laboratories, and was higher overall in HMO
than in GH laboratories (Table 2). Of note, laboratory no. 13
had a higher number of positive isolates in the ﬁrst period,
probably due to lack of a sample rejection/acceptance policy,
leading to repeat testing and reporting of positive samples
(Table 1).
We constructed a multivariable analysis that included the
diagnostic method, the period and the institution type. The
proportion positive was signiﬁcantly lower in GH compared
with HMO laboratories: OR 0.726 (95% CI 0.664–0.795,
p <0.001) for GH group 1, OR 0.841(95% CI 0.764–0.926,
p <0.001) for GH group 2 and OR 0.438 (95% CI 0.309–0.621,
p <0.001) for GH group 3 versus HMO laboratories, respec-
tively. The proportion positive was higher in the laboratories
using the CDT PCR method (alone or combined with GDH)
compared with that in laboratories using CDT EIA alone (OR
1.342, 95% CI 1.245–1.447, p <0.001) or GDH/CDT
combined testing without CDT PCR (OR 1.128, 95% CI
1.034–1.135, p 0.007).
Proportion of positive tests using CDT EIA, GDH antigen and
CDT PCR during the second period of the survey
The proportion of positive samples using each of the three
methods (CDT EIA, GDH antigen and CDT PCR) during the
second period was compared (Table 3). We excluded from
the analysis, laboratories that performed CDT PCR as their
sole method (4 and 7) and laboratories that did not have
detailed documentation of GDH results (3 and 11). The total
proportions of GDH+/CDT+ samples and GDH+/CDT
samples were 10.3% and 7.8%, respectively. CDT PCR was
performed in 9 of 14 laboratories, on a total of 608 of 1370
GDH+/CDT samples (44%). It was positive in 334 of 608
samples (53%), with proportion positive in each laboratory
ranging from 36% to 87%.
TABLE 1. General characteristics of clinical laboratories participating in the survey
Lab. no. Methods used in second perioda Trans dateb Reports, mon (1st/2nd) Rejection criteriac Criteria apply?d
Tertiary care hospitals
1 GDH/CDT+PCR 03/12 11/10 2–5 2nd
2 GDH/CDT only 09/10 12/12 2,3,5 Both
3 GDH/CDT+PCR 08/11 13/12 2,3,5 Both
4 CDT PCR 05/12 16/3 2–5 Both
General hospitals, >400 beds
5 GDH/CDT only 01/11 12/12 2,4 2nd
6 GDH/CDT+PCR 03/11 12/12 2,3 2-both, 3-2nd
7 CDT PCR 03/11 12/12 2–5 2,5-both, 3-4-2nd
8 GDH/CDT+PCR 07/12 12/8 2–5 2nd
9 GDH/CDT only 02/12 12/8 3–5 Both
10 GDH/CDT+PCR 05/12 8/8 2–5 2,5-both, 3-4-2nd
11 GDH/CDT onlye 01/11 12/9 1,3,5 2nd
General hospitals, <400 beds
12 GDH/CDT onlyf 04/11 12/12 1–5 Both
13 GDH/CDT only 09/10 12/12 2–3 2nd
Health maintenance organization laboratories
14 GDH/CDT+PCR 07/12 6/8 None NA
15 GDH/CDT only 12/11 12/12 None NA
16 GDH/CDT+PCR 08/11 12/12 2–5 2-3,5-both, 4-2nd
17 GDH/CDT only 12/10 12/12 2,3,5 Both
18 GDH/CDT only 06/12 12/12 2–3 Both
aMethods used in the second period (ﬁrst period-testing of Clostridium difﬁcile toxin by EIA method): CDT PCR, C. difﬁcile toxin (CDT) PCR; glutamate dehydrogenase antigen
(GDH)/CDT+PCR, combined GDH/CDT testing, with CDT PCR performed for most cases (>90%) of GDH-positive, CDT-negative samples; GDH/CDT only, combined GDH/
CDT testing, with CDT PCR performed for the minority of GDH-positive, CDT-negative samples.
bTrans date: the transition date between the periods (MM/YY).
cRejection criteria: 1, requires infectious diseases specialist authorization; 2, rejection of formed stool samples; 3,4, rejection of samples from a recently positive- or negative-tested
patient, respectively; 5, rejection of samples from infants.
dImplementation of rejection criteria during the two periods of the survey.
eCDT PCR was implemented for testing of all GDH-positive, CDT-negative samples in the last 3 months of the survey.
fGDH/CDT testing was used in the ﬁrst 9 months of the second period, and CDT PCR was used for all samples in the following 3 months.
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Discussion
The past decade has been notable for dramatic changes in the
epidemiology and morbidity of CDI in North America and
other parts of the developed world [1]. At the same time, new
diagnostic methods have become available, allowing improved
sensitivity in CDI diagnosis. Consequently, the evaluation of
CDI incidence, especially on a national level, has become
problematic, as detailed data regarding the methodology used
by each clinical laboratory are difﬁcult to collect and interpret.
In this study, we performed the ﬁrst national survey evaluating
the effect of methodological changes on the proportion of
positive samples. Although a minority of the laboratories
elected not to participate, we were able to collect data from
almost all laboratories providing diagnostic services to com-
munity clinics and LTCFs, and to c.65% of the GH service beds.
Through this study, we were able to represent the effects of
progress in CDI diagnostic methods on the proportion
positive in a large variety of different institutions and to
highlight the pitfalls that can be expected.
In our survey we found that by the time of the onset of the
study, only 3 of 21 laboratories (14%) were using CDT EIA
alone for the diagnosis of CDI. This percentage is lower than
that reported in Australia, where 60% were still using CDT EIA
alone [8]. However, at the time of that survey (2009 to early
2010) [8], all of the laboratories in Israel were still using CDT
EIA (the implementation of the new methods had started by
late 2010, long before the publication of the ofﬁcial Israeli
guidelines). Among the remaining 18 laboratories, nine were
testing also for GDH antigen (group B) and nine were using
CDT PCR alone or combined with GDH/CDT testing (group
A), as recommended by Israeli and other national guidelines
[5,6]. The reason for not performing conﬁrmatory testing by
CDT PCR in the case of equivocal results (e.g., GDH+/CDT)
was not solicited in this survey, but was likely to be either
ﬁnancial constraints or availability difﬁculties (personal com-
munications).
Our results demonstrated two main factors associated with
the proportion of positive samples. We found that laborato-
ries using CDT PCR alone or following GDH screening (group
A) had a higher proportion, compared with those using CDT
EIA, either alone (during the ﬁrst period) or combined with
GDH (during the second period in group B). The results of the
multivariable analysis suggest that this difference is due not to
variation in the epidemiology between the periods, but rather
to differences in testing methods. Although this ﬁnding
suggests that CDT PCR testing is likely to improve the
detection of CDI, one must bear in mind that with it comes the
potential for over-diagnosis of CDI, due both to analytical
false-positive results and testing of asymptomatic carriers of
C. difﬁcile.
Surprisingly, CDT EIA testing (by various assays) alone was
associated with a higher proportion positive than was CDT
TABLE 2. Temporal trends in samples’ rejection and positivity proportions
Lab. Methods in second period
First perioda Second perioda
D proportion
rejected (P)
D proportion
positive (P)Total Rejected (%) Pos. (%)b Total Rejected (%) Pos. (%)b
1 GDH/CDT+PCR 3350 557 (16.6) 211 (7.6) 3124 901 (28.8) 297 (13.4) 12.2 (<0.001) 5.8 (<0.001)
2 GDH/CDT only 3930 90 (2.3) 289 (7.5) 4383 196 (4.5) 236 (5.6) 2.2 (<0.001) 1.9 (<0.001)
3 GDH/CDT+PCR 1863 263 (14.1) 193 (12.1) 2080 310 (14.9) 199 (11.2) 0.8 (0.484) 0.9 (0.459)
4 CDT PCR 4420 369 (8.3) 336 (8.3) 1524 33 (2.1) 187 (12.5) 6.2 (<0.001) 4.2 (<0.001)
5 GDH/CDT only 903 11 (1.2) 124 (13.9) 951 62 (6.5) 38 (4.3) 5.3 (<0.001) 9.6 (<0.001)
6 GDH/CDT+PCR 1479 35 (2.4) 100 (6.9) 1514 35 (2.3) 167 (11.3) 0.1 (0.921) 4.4 (<0.001)
7 CDT PCR 1302 206 (15.8) 89 (8.1) 1231 485 (39.4) 76 (10.1) 23.6 (<0.001) 2 (0.127)
8 GDH/CDT+PCR 396 43 (10.9) 30 (8.5) 234 29 (12.4) 26 (12.7) 1.5 (0.559) 4.3 (0.055)
9 GDH/CDT only 2057 31 (1.5) 220 (10.9) 1512 34 (2.2) 149 (10.1) 0.7 (0.102) 1.2 (0.459)
10 GDH/CDT+PCR 571 72 (12.6) 29 (5.8) 701 225 (32.1) 80 (16.8) 29.5 (<0.001) 11 (<0.001)
11c GDH/CDT only 1064 16 (1.5) 131 (12.5) 810 29 (3.6) 81 (10.3) 2.1 (<0.001) 2.2 (0.16)
12d GDH/CDT only 403 8 (2) 10 (2.5) 314 8 (2.5) 25 (7.9) 0.5 (0.613) 5.4 (<0.001)
13 GDH/CDT only 1146 29 (2.5) 480 (43) 628 125 (19.9) 64 (12.7) 17.4 (<0.001) 30.3 (<0.001)
14 GDH/CDT+PCR 443 34 (7.7) 24 (5.9) 921 15 (1.6) 101 (11.1) 6.1 (<0.001) 5.2 (<0.001)
15 GDH/CDT only 525 0 45 (8.6) 543 0 79 (14.5) 0 5.9 (<0.001)
16 GDH/CDT+PCR 1095 101 (9.2) 136 (13.7) 918 28 (3.1) 91 (10.2) 6.1 (<0.001) 3.5 (<0.001)
17 GDH/CDT only 4391 385 (8.8) 837 (20.9) 4234 375 (8.9) 792 (20.5) 0.1 (0.884) 0.4 (0.685)
18 GDH/CDT only 1638 709 (43.3) 113 (12.2) 1875 933 (49.8) 141 (15) 5.3 (<0.001) 2.8 (0.08)
Tertiary care hospitals 13563 1279 (9.4) 1029 (8.4) 11111 1440 (13) 919 (9.5) 3.6 (<0.001) 1.1 (0.004)
General hospital, >400 bed 7772 414 (5.3) 723 (9.8) 6953 899 (12.9) 617 (10.2) 7.6 (<0.001) 0.4 (0.482)
General hospital, <400 bed 1549 37 (2.4) 490 (32.4) 942 133 (14.1) 89 (11) 11.7 (<0.001) 21.4 (<0.001)
HMO laboratories 8092 1229 (15.2) 1155 (16.8) 8491 1351 (15.9) 1024 (16.9) 0.7 (0.199) 0.1 (0.958)
PCR or GDH/CDT+PCR 14919 1680 (11.3) 1148 (8.7) 12247 2061 (16.8) 1224 (12) 5.5 (<0.001) 3.3 (<0.001)
GDH/CDT only 16057 1279 (8.0) 2249 (15.2) 15250 1762 (11.5) 1605 (11.9) 3.5 (<0.001) 3.3 (<0.001)
Total 30976 2959 (9.5) 3397 (12.1) 27497 3823 (13.9) 2829 (11.94) 4.4 (<0.001) 0.1 (0.543)
aFirst period, testing of Clostridium difﬁcile toxin (CDT) by EIA method by all laboratories, second period, change to methods as described in second column.
bProportion positive was calculated among the accepted samples.
cCDT PCR was implemented for all glutamate dehydrogenase antigen (GDH) -positive, CDT-negative samples in the last 3 months of the survey.
dGDH/CDT alone was used in the ﬁrst 9 months of the second period, and CDT PCR was used in the following 3 months. For comparison, data from the ﬁrst 9 months only are
presented. In the 3 months of CDT PCR use, 125 samples were tested, of which 11 (8.8%) were positive.
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EIA performed in the context of the combined GDH/CDT C.
Diff Quik Chek Complete lateral ﬂow assay (TECHLAB).
Indeed, the average sensitivity (compared with CDT PCR)
was only 59% with a range of 50–75%. These results are
similar to previous studies in which the sensitivity values of
CDT EIA were 48–78% [14–17]. They are also consistent
with many studies that found variable sensitivity and speciﬁcity
values in different EIA [4]. Due to the nature and design of
our study, it was difﬁcult to accurately compare different
CDT EIA in use by different laboratories. Our results do,
however, highlight two important messages: (i) it is critical to
validate any new assay, including commercial PCR assays, with
the ‘gold standard’ method, either toxigenic culture or cell
culture cytotoxicity neutralization assay, as the analytical
parameters of similar methods may differ signiﬁcantly, and (ii)
in laboratories that are shifting from CDT EIA to GDH-based
testing for CDI, it is essential to perform conﬁrmatory CDT
testing by methods other than EIA alone (e.g., CDT PCR),
because of the low sensitivity of EIA and the variable
proportions of toxigenic versus non-toxigenic strains in
different populations.
Overall, the proportion of samples rejected increased
during the second period, and the extent of the change was
particularly high in laboratories that applied or added rejection
criteria in the second period. In contrast, the proportion of
rejected samples decreased in the two laboratories that did
not apply any criteria. Surprisingly, HMO-afﬁliated laboratories
also had a high proportion of positive samples. Considering
that direct communication between clinicians and laboratories,
and therefore appropriate use of laboratory tests, is not
expected to be more common in the community than in the
GH, this difference probably reﬂects an actual difference in
epidemiology, e.g. the LTCF versus the GH population.
Regrettably, we could not differentiate between tests origi-
nating from community patients and those from LTCFs to
further explore the source of this difference. Other effects of
the change in rejection policy on the proportion positive
varied in the different groups. Of note, in laboratory no. 13, we
initially observed a very high proportion of positive samples,
most likely through the lack of any rejection policy. The
proportion decreased following the application of rejection
criteria (Table 2, Fig. 1). These changes are indicative of the
tremendous effect that diagnostic strategies, both pre-analyt-
ical and analytical, may exert on the reported incidence, and
thereby on inﬂuence surveillance, both within and among
medical facilities.
This study has a number of limitations, inherent to its
design. First, it was not designed to provide a head-to-head
methodological comparison nor an accurate estimation of CDI
incidence. Second, the inter-laboratory variability in the study
dates complicates the evaluation of possible regional epidemi-
ological changes (e.g. the emergence of an epidemic strain) that
might have had an effect on the proportion of positive tests.
Finally, our inability to distinguish between community-onset
and LTCF-related cases diagnosed at the HMO laboratories,
prevent us from discerning differences related to these two
very different populations, and therefore limit our ability to
compare the results of the HMO and the GH laboratories.
Despite these limitations, our study met its objectives, and it
provides unique, valuable data from a national perspective
regarding recent advances in CDI diagnosis. It highlights that in
addition to comparative methodological studies, national
surveys are necessary to improve the standardized application
of new methods and to evaluate their effects in real-life
conditions.
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